{"schema_version":"secwatch.filing_event.v1","accession":"0001658247-26-000044","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2026-06-22T20:16:16+00:00","discovered_at":"2026-06-22T20:17:01.411664+00:00","generated_at":"2026-06-22T20:17:55.185940+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Crinetics shareholders elect three Class II directors, ratify PwC, approve say-on-pay","bullets":["Elected Caren Deardorf (73.5M for), Weston Nichols (90.2M for), and Stephanie S. Okey (72.2M for) to 2029 terms.","Ratified PricewaterhouseCoopers LLP as independent auditor for FY2026: 101.7M for, 342K against, 12.7K abstain.","Advisory vote on named executive officer compensation approved: 91.7M for, 2.7M against, 2.6M abstain, 5.0M broker non-votes.","Approximately 97% of outstanding shares (102,030,415) were represented at the meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001658247-26-000044","json":"https://secwatch.observer/filing/0001658247-26-000044.json","markdown":"https://secwatch.observer/filing/0001658247-26-000044.md","text":"https://secwatch.observer/filing/0001658247-26-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000165824726000044/0001658247-26-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000165824726000044/crnx-20260618.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T20:17:55.185940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5506292516ae34f7f7324ef66260fdeab7c5c29c","claim":"Crinetics Pharmaceuticals, Inc. shareholders approved Election of three Class II directors to the Board of Directors for three-year terms to expire at the 2029 annual meeting of stockholders. at the 2026-06-18 meeting.","evidence_excerpt":"The Company’s stockholders approved the election of three Class II directors to the Board of Directors for three-year terms to expire at the 2029 annual meeting of stockholders. The results of such vote were: Votes For Votes Withheld Broker Non-Votes Caren Deardorf 73,454,076 23,532,328 5,044,011 Weston Nichols, Ph.D. 90,208,564 6,777,840 5,044,011 Stephanie S. Okey, M.S. 72,225,313 24,761,091 5,044,011","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000165824726000044/0001658247-26-000044-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-18"}],"fact_type":"shareholder_vote"},{"claim_id":"8bcd77c8a2d72a35c074aad40259eaddda3c3962","claim":"Crinetics Pharmaceuticals, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-18 meeting.","evidence_excerpt":"The Company’s stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The results of such vote were: Votes For Votes Against Abstentions 101,675,974 341,727 12,714","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000165824726000044/0001658247-26-000044-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-18"}],"fact_type":"shareholder_vote"},{"claim_id":"e2c6190614200d55d63df7acb9bf53147080a35e","claim":"Crinetics Pharmaceuticals, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers. at the 2026-06-18 meeting.","evidence_excerpt":"The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers. The results of such vote were: Votes For Votes Against Abstentions Broker Non-Votes 91,657,992 2,698,538 2,629,874 5,044,011","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000165824726000044/0001658247-26-000044-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-18"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}